Survodutide, a glucagon and GLP-1 dual receptor agonist developed by Boehringer Ingelheim, has demonstrated cardiovascular safety in a phase 3 trial for high-risk patients. The SYNCHRONIZE-CVOT study (NCT06077864), directed by Biykem Bozkurt, MD, PhD, evaluated the drug’s safety in individuals with obesity, regardless of diabetes status, who also had established cardiovascular disease or chronic kidney disease. This marked the first time a dual agonist underwent rigorous cardiovascular outcomes testing in such a vulnerable group.
Obesity contributes to a range of metabolic disorders, including type 2 diabetes, hypertension, and cardiovascular disease, which remains the leading cause of death among affected individuals. Bozkurt noted that traditional weight-loss therapies often overlook a critical factor: the type of fat lost. Visceral and dysfunctional fat, rather than subcutaneous fat, pose the greatest long-term risks to heart and metabolic health. The study showed that simply reducing weight is insufficient without addressing fat distribution and metabolic function.
The drug’s dual mechanism distinguishes it from existing treatments. GLP-1 receptor activation enhances satiety, improves insulin sensitivity, and supports weight loss, while glucagon receptor activation delivers additional metabolic benefits. These include reduced liver fat accumulation, increased breakdown of fatty acids, and higher energy expenditure. Unlike prior GLP-1-only medications, survodutide targets both fat storage and energy utilization, potentially addressing gaps left by single-target approaches.
The trial’s structure addressed lingering concerns about glucagon’s cardiovascular impact. The non-inferiority design ensured no increased risk for patients with coronary artery disease, prior myocardial infarctions, or heart failure. This was essential given glucagon’s historical association with adverse cardiac events in specific contexts.
Findings from the study were shared at the 2026 American Heart Association Scientific Sessions and published in The Lancet. The results suggest the drug may provide advantages beyond weight reduction alone, though its integration into clinical practice will depend on comparisons with established therapies.
